Patents by Inventor Kathy Otis

Kathy Otis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF AN ANTI-B-CORONAVIRUS ANTIBODY IN A SAMPLE
    Publication number: 20230258638
    Abstract: Disclosed herein are methods, kits, systems, algorithms and improvements for detecting the presence of or determining an amount, quantity, concentration and/or level of an antibody against at least one type of ?-coronavirus, such as, for example, an antibody against SARS-CoV or SARS-CoV-2, in one or more samples obtained from a subject. In some aspects, the methods, kits and systems relate to detecting the presence of or determining an amount, quantity, concentration and/or level of at least one type of anti-?-coronavirus antibody, such as an IgG and/or IgM antibody, in one or more samples obtained from a subject.
    Type: Application
    Filed: October 12, 2022
    Publication date: August 17, 2023
    Inventors: A. Scott Muerhoff, John C. Prostko, James L. Stewart, Mary A. RODGERS, Gavin A. CLOHERTY, James Hartnett, Jeff Moore, Kathy Otis, Alak Kar, Bailin Tu, Bryan Tieman, Carolyn Strobel, David Hawksworth, Robert Ziemann, Zhihong Lin, Chris Marohnic, Peter Wiebe, Todd Meyer, Weijie Jiao, Gangamani S. Beligere, Saminathan X. Muthusamy, Jessica L. Grieshaber, Sandra K. Pearce, Edwin C. Frias, Russell E. Taylor, Kelly Coller, Yangrong E. Zhang, Thomas T. Biegalski, David J. Daghfal, Claudio Galli, Sergey Y. Tetin, Qiaoqiao Ruan, Patrick MacDonald, Michael S. Cassidy, Mary E. Gardiner, Mary Ann P. Palafox, Matthew S. Matias, Melissa B. Brennan, Philip W. Schultz, Beth C. Trudeau
  • Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
    Patent number: 11428694
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: August 30, 2022
    Assignee: ABBOTT LABORATORIES
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20210231665
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Application
    Filed: April 15, 2021
    Publication date: July 29, 2021
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20200141937
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Application
    Filed: May 24, 2019
    Publication date: May 7, 2020
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20200033344
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.
    Type: Application
    Filed: August 13, 2019
    Publication date: January 30, 2020
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis, Andrea Branch, Francis Eng
  • Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
    Patent number: 10444242
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: October 15, 2019
    Assignees: ABBOTT LABORATORIES, ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis, Andrea Branch, Francis Eng
  • Detection methods employing HCV core lipid and DNA binding domain monoclonal antibodies
    Patent number: 10345311
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: July 9, 2019
    Assignee: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV core lipid binding domain monoclonal antibodies
    Patent number: 10197573
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: February 5, 2019
    Assignee: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20170052184
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of HCV core protein and the DNA binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of HCV core protein.
    Type: Application
    Filed: June 22, 2016
    Publication date: February 23, 2017
    Inventors: ROBERT ZIEMANN, APRIL AHLBERG, DAVID HAWKSWORTH, BRYAN TIEMAN, A. SCOTT MUERHOFF, CHRISTOPHER MAROHNIC, KATHY OTIS, ANDREA BRANCH, FRANCIS ENG
  • DETECTION METHODS EMPLOYING HCV CORE LIPID AND DNA BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20170052183
    Abstract: The present disclosure provides detection methods employing HCV core lipid binding domain and DNA binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of HCV core protein.
    Type: Application
    Filed: June 22, 2016
    Publication date: February 23, 2017
    Inventors: ROBERT ZIEMANN, APRIL AHLBERG, DAVID HAWKSWORTH, BRYAN TIEMAN, A. SCOTT MUERHOFF, CHRISTOPHER MAROHNIC, KATHY OTIS
  • HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20160291020
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Application
    Filed: March 23, 2016
    Publication date: October 6, 2016
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV core lipid binding domain monoclonal antibodies
    Patent number: 9371374
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: June 21, 2016
    Assignee: ABBOTT LABORATORIES
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis
  • HCV CORE LIPID BINDING DOMAIN MONOCLONAL ANTIBODIES
    Publication number: 20140272931
    Abstract: The present invention relates to monoclonal antibodies for the detection of HCV antigen. More specifically, the invention describes antibodies against HCV core antigen lipid binding domain and immunoassay methods, kits and compositions for use in detecting HCV infection.
    Type: Application
    Filed: December 23, 2013
    Publication date: September 18, 2014
    Applicant: Abbott Laboratories
    Inventors: Robert Ziemann, April Ahlberg, David Hawksworth, Bryan Tieman, A. Scott Muerhoff, Christopher Marohnic, Kathy Otis